Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

The axing of some 10,000 programs has consigned untold numbers of children and refugees to death, officials say. Documents ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

The Food and Drug Administration (FDA) has accepted under Priority Review the New Drug Application (NDA) for lenacapavir, a long-acting HIV-1 capsid inhibitor, for the prevention of HIV as ...

Older women with HIV face complex, intersectional challenges that warrant more support, according to a scoping review with ...

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...

The monologue-style drama is about a mother torn between love for her gay son and her conservative husband and faith ...

Baystate Wing Hospital in Palmer, Mass., has contacted an unknown number of patients who may have been exposed to hepatitis or HIV due to a potential sterilization issue during surgeries performed ...